UMIN試験ID | UMIN000041927 |
---|---|
受付番号 | R000047710 |
科学的試験名 | 肝細胞癌に対する体幹部定位放射線治療とラジオ波焼灼術の比較:メタアナリシスと系統的レビュー |
一般公開日(本登録希望日) | 2020/10/01 |
最終更新日 | 2022/07/29 15:41:53 |
日本語
肝細胞癌に対する体幹部定位放射線治療とラジオ波焼灼術の比較:メタアナリシスと系統的レビュー
英語
Comparison between stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Meta-analysis and systematic review.
日本語
肝細胞癌に対する体幹部定位放射線治療とラジオ波焼灼術の比較:メタアナリシスと系統的レビュー
英語
Comparison between stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Meta-analysis and systematic review.
日本語
肝細胞癌に対する体幹部定位放射線治療とラジオ波焼灼術の比較:メタアナリシスと系統的レビュー
英語
Comparison between stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Meta-analysis and systematic review.
日本語
肝細胞癌に対する体幹部定位放射線治療とラジオ波焼灼術の比較:メタアナリシスと系統的レビュー
英語
Comparison between stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Meta-analysis and systematic review.
日本/Japan |
日本語
肝細胞癌
英語
Hepatocellular carcinoma
消化器内科学(消化管)/Gastroenterology | 放射線医学/Radiology |
悪性腫瘍/Malignancy
いいえ/NO
日本語
英文参照
英語
In the Barcelona Clinic Liver Cancer staging and treatment strategy (BCLC) guideline, surgery, radiofrequency ablation (RFA), and trans-arterial chemoembolization (TACE) are considered as standard treatment for hepatocellular carcinoma (HCC). Although stereotactic body radiotherapy (SBRT) has been recognized as novel local therapy for HCC, SBRT is still not mentioned in BCLC guideline due to lack of randomized control trials. Recently, meta-analysis which compared SBRT and RFA for HCC has published. However, reports analyzed in the meta-analysis were heterogeneous in quality. In recent years, there are several retrospective studies which compared SBRT and RFA using propensity score matching (PSM). Aim of current meta-analysis is to summarize data from quality studies compared SBRT and RFA using PSM.
有効性/Efficacy
日本語
英語
日本語
全生存期間のハザード比
英語
Hazard ratio of overall survival
日本語
英語
その他・メタアナリシス等/Others,meta-analysis etc
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
適用なし/Not applicable |
適用なし/Not applicable |
男女両方/Male and Female
日本語
英文参照
英語
We will include observational studies using propensity score matching that compared SBRT and RFA for HCC. Articles were published as full reports, brief reports, or conference abstracts, regardless of their primary end point. Non-English reports were excluded.
日本語
英文参照
英語
NA
日本語
名 | 貴久 |
ミドルネーム | |
姓 | 江里口 |
英語
名 | Takahisa |
ミドルネーム | |
姓 | Eriguchi |
日本語
大船中央病院
英語
Ofuna Chuo Hospital
日本語
放射線治療センター
英語
Radiation Oncology Center
2470056
日本語
鎌倉市大船
英語
6-2-24
0467452111
eriguchitakahisa@gmail.com
日本語
名 | 貴久 |
ミドルネーム | |
姓 | 江里口 |
英語
名 | Takahisa |
ミドルネーム | |
姓 | Eriguchi |
日本語
大船中央病院
英語
Ofuna Chuo Hospital
日本語
放射線治療センター
英語
Radiation Oncology Center
2470056
日本語
鎌倉市大船
英語
6-2-24
0467452111
eriguchitakahisa@gmail.com
日本語
その他
英語
Ofuna Chuo Hospital
日本語
大船中央病院
日本語
日本語
英語
日本語
無し
英語
NA
日本語
なし
日本語
その他/Other
日本語
英語
日本語
英語
日本語
英語
日本語
該当なし
英語
NA
日本語
該当なし
英語
NA
0467452111
eriguchitakahisa@gmail.com
いいえ/NO
日本語
英語
日本語
英語
2020 | 年 | 10 | 月 | 01 | 日 |
N/A
最終結果が公表されている/Published
https://pubmed.ncbi.nlm.nih.gov/33856722/
2107
日本語
英文参照
英語
Three BCLC factor matched studies were identified. Stereotactic body radiotherapy led to comparable OS and significantly better LC. We also identified three additional BCLC factor unmatched studies. However, considerable heterogeneity was observed for HR of OS between BCLC factor matched and unmatched studies.
2022 | 年 | 07 | 月 | 29 | 日 |
日本語
英語
日本語
英文参照
英語
In the selected six studies, 2107 patients with HCC treated with SBRT or RFA were analyzed; 1241 and 866 patients were categorized as having RFA and SBRT, respectively. Basic information about the included studies is summarized in Table 1, and the clinical information is shown in Table 2. Hara et al. included 13.2% of hypofractionated radiotherapy. The total NOS score to assess the quality of observational studies was 9 points in one study, 8 points in three studies, and 7 points in two studies (a score of 9 suggests the best study quality) (Table S4). We requested the authors to provide the HR for OS or LC and log rank of p values that were unavailable in the studies by Wahl et al. and Hara et al. The HR for OS in the study by Feng et al. was calculated from the Kaplan Meier curve in their poster. Information in Tables 1 and 2 was not only from articles and abstracts but also from posters and data provided by authors.
日本語
英文参照
英語
N/A
日本語
英文参照
英語
Complications related to treatments were available in four studies. The rates of grade 3 or higher toxicities ranged from 0 to 11 percent, which were not significantly different between RFA and SBRT. The uncompensated liver cirrhosis and liverrelated deaths 12 months after treatment was significantly higher in the SBRTHFRT in the report by Hara et al. However, the 3year liver failure mortalities after propensity score matching were similar (p, 0.52). Although CP score deterioration more than 2 at 3 months was higher in patients treated with SBRT in the report by Kim et al.8 it recovered at 6 months posttreatment (p, 0.278).
日本語
英文参照
英語
The adjusted HR for OS as the primary endpoint was assessed based on six retrospective studies consisting of 2107 patients. A randommodel metaanalysis of these studies comprised 866 patients who underwent SBRT and 1241 patients who underwent RFA, the three metaanalyses of BCLCfactormatched studies revealed that SBRT led to equivalent OS compared with RFA. We identified three additional PS studies that did not use BCLCfactors in the PS analysis. Among them, the HR of OS was significantly higher in RFA than in SBRT. However, considerable heterogeneity was observed in the HR of OS between BCLCfactomatched and unmatched studies.
日本語
英語
日本語
英語
試験終了/Completed
2020 | 年 | 10 | 月 | 01 | 日 |
2020 | 年 | 10 | 月 | 01 | 日 |
2020 | 年 | 10 | 月 | 01 | 日 |
2020 | 年 | 10 | 月 | 01 | 日 |
日本語
英文参照
英語
Study Search
We will systematically search PubMed, the Cochrane database, EMBASE, and Web of Science as of October 1, 2020. The search strategy for PubMed will be as follows:
(hepatoma[title] OR hepatomas[title] OR HCC[title] OR ((hepatocellular[title] OR hepatic[title] OR liver[title]) AND (cancer[title] OR carcinoma[title] OR malignancy[title] OR tumor[title] OR neoplasm[title] OR neoplasms[title] OR carcinomas[title] OR malignancies[title]))) AND (RFA OR ((radiofrequency OR thermal) AND (ablation OR ablative))) AND (SBRT OR SRT OR SABR OR stereotactic OR radiotherapy OR radiation OR irradiation) AND (randomized OR randomized OR RCT OR randomly OR phase III OR phase 3 OR propensity OR PSM OR Inverse probability of treatment weighting OR Doubly Robustness)
Reference lists in the included articles and review articles will be also hand searched.
Data synthesis
HR from propensity score matched studies will be pooled. Prior to generic inverse variance meta-analysis using RevMan 5.0 (Cochrane Collaboration, London, UK), HR will be log converted.
Subgroup analyses which focus on liver function will be performed.
Statistical significance will be judged by P < 0.05.
2020 | 年 | 09 | 月 | 29 | 日 |
2022 | 年 | 07 | 月 | 29 | 日 |
日本語
https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000047710
英語
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047710
研究計画書 | |
---|---|
登録日時 | ファイル名 |
研究症例データ仕様書 | |
---|---|
登録日時 | ファイル名 |
研究症例データ | |
---|---|
登録日時 | ファイル名 |